VitaSpring Biomedical Co. Ltd.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $5.6M | $248.2K | $15.1K | $17.2K |
| Cost of Revenue | $0 | $0 | $0 | $3.3M | $3.5M | $136.0K | $13.4K | $3.5K |
| Gross Profit | $0 | $0 | $0 | $-3.3M | $2.1M | $112.2K | $1.7K | $13.7K |
| Gross Margin | — | — | — | — | 36.8% | 45.2% | 11.2% | 79.8% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $385.4K | $679.9K | $1.1M | $844.8K | $941.3K | $537.6K | $21.2K | $36.1K |
| Operating Income | $-385.4K | $-679.9K | $-1.1M | $-4.2M | $1.1M | $425.4K | $6.9K | $-22.4K |
| Operating Margin | — | — | — | — | 20.1% | 171.4% | 45.7% | -130.4% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-385.4K | $-679.9K | $-1.1M | $-4.2M | $1.1M | $-425.4K | $6.9K | $-22.4K |
| Income Tax Expense | $30.0K | $95.0K | $0 | $-5.4K | $217.1K | $0 | $0 | $0 |
| Net Income | $-415.4K | $-774.9K | $-1.1M | $-4.2M | $909.6K | $425.4K | $6.9K | $-22.4K |
| Net Margin | — | — | — | — | 16.2% | 171.4% | 45.7% | -130.4% |
| EPS (Basic) | — | — | — | — | — | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | $0.00 | $0.00 | $-0.01 | $-0.02 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | — | — | — | — | 412.0M | 182.2M | — | — |
| Shares Outstanding (Diluted) | 207.0M | 207.0M | 207.0M | 206.5M | 206.0M | 182.2M | 21.8M | 157.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |